We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease ... Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). Show more
Presentation to highlight baseline characteristics of Spruceโs CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current...
CAHmelia-203 Study of Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia (CAH) with Severe Hyperandrogenemia Did Not Meet Primary Efficacy Endpoint Positive Data from CAHptain-205 Study...
CAHmelia-203 Study of Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia (CAH) with Severe Hyperandrogenemia Did Not Meet Primary Efficacy Endpoint Positive Data from CAHptain-205 Study...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet...
100 Patients Enrolled, Exceeding Target Enrollment of 90 Patients Topline Results for CAHmelia-204 Anticipated in the Third Quarter of 2024 Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage...
Baseline Characteristics Reinforce Study Enrichment Strategy in Adult Classic Congenital Adrenal Hyperplasia (CAH) Program Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical...
Catalyst-Heavy 2024 with Topline Results from CAHmelia-203 in Adult Classic Congenital Adrenal Hyperplasia (CAH) and CAHptain-205 in Pediatric Classic CAH Anticipated in March 2024 Topline...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.7 | 0.7488 | 0.6711 | 590145 | 0.69966152 | CS |
4 | -0.11 | -13.5802469136 | 0.81 | 0.8698 | 0.6711 | 706691 | 0.75870732 | CS |
12 | -2.76 | -79.7687861272 | 3.46 | 5.95 | 0.6711 | 1418863 | 1.5496045 | CS |
26 | -0.42 | -37.5 | 1.12 | 5.95 | 0.6711 | 768484 | 1.64702135 | CS |
52 | -1.39 | -66.5071770335 | 2.09 | 5.95 | 0.6711 | 436962 | 1.71990019 | CS |
156 | -16.3 | -95.8823529412 | 17 | 17.58 | 0.6711 | 645566 | 3.38700204 | CS |
260 | -16.3 | -95.8823529412 | 17 | 35.6 | 0.6711 | 559653 | 3.74522871 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions